Daily Endocrinology Research Analysis
Analyzed 148 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial showed that real-time continuous glucose monitoring outperformed self-monitoring of blood glucose in adults with type 2 diabetes on modern pharmacotherapy. A mechanistic study identified a glycine–GLRA1–calmodulin axis that maintains endoplasmic reticulum calcium to sustain insulin secretion and β-cell survival. An AI-enabled analysis of 115,683 radiology reports quantified the prevalence and consequences of incidental thyroid findings, highlighting overdiagnosis cascades.
Research Themes
- Digital diabetes technologies and glycemic outcomes
- Amino acid signaling and ER calcium homeostasis in β-cells
- AI-driven detection and management pathways for incidental thyroid findings
Selected Articles
1. Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial.
In a 24-center UK randomized, open-label superiority trial (n=303), real-time CGM improved glycemic control compared with SMBG among adults with type 2 diabetes treated with basal insulin plus SGLT2i/GLP-1RA/dual GIP/GLP-1RA. Benefits were observed during both self-management and clinician-supported phases.
Impact: This pragmatic RCT provides contemporary evidence that CGM adds value beyond SMBG even when potent glucose-lowering agents are used, informing technology adoption and guidelines.
Clinical Implications: Consider offering CGM to adults with T2D on basal insulin plus incretin/SGLT2 therapy to improve glycemic outcomes; plan for implementation workflows that support both self-management and clinician oversight.
Key Findings
- Randomized 303 adults with T2D to real-time CGM versus SMBG across 24 UK centers.
- CGM produced superior glycemic control versus SMBG during self-managed and clinician-supported periods.
- Participants were on basal insulin plus SGLT2i, GLP-1RA, or dual GIP/GLP-1RA, reflecting modern therapy.
Methodological Strengths
- Multicenter randomized superiority design reflecting real-world therapy patterns
- Clear comparator (SMBG) with pragmatic implementation across settings
Limitations
- Open-label design may introduce performance bias
- Abstract lacks detailed duration and quantitative effect sizes
Future Directions: Assess cost-effectiveness, longer-term outcomes (hypoglycemia, hospitalizations), and equity of CGM access; evaluate tailored clinician-support models.
BACKGROUND: Type 2 diabetes is the most common metabolic disorder worldwide, accounting for about 90% of people living with diabetes. Glycated haemoglobin (HbA METHODS: This open-label, parallel-design, randomised controlled trial conducted across 24 primary and secondary care centres in the UK enrolled adults with type 2 diabetes managed with basal insulin and SGLT2 inhibitors or GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists with HbA FINDINGS: Between July 26, 2023, and Jan 31, 2025, 469 individuals underwent screening for potential study inclusion, 140 were excluded due to not meeting inclusion criteria, and 329 were included in the baseline phase of the study. 26 individuals were then excluded due to insufficient data capture or withdrawal, and 303 participants were randomly assigned; 198 to the CGM intervention group and 105 to the SMBG control group. 204 (67%) participants were male and 99 (33%) were female, the mean age of the cohort was 60·7 years (SD 9·8), and mean diabetes duration was 16·7 years (6·9). Baseline HbA INTERPRETATION: In adults with type 2 diabetes on basal insulin plus modern therapies, real-time CGM improved glycaemic control versus SMBG during self-management and under clinician-supported management. FUNDING: Abbott Diabetes Care.
2. Glycine-GLRA1-calmodulin signaling regulates endoplasmic reticulum calcium to sustain insulin secretion and β-cell function.
This mechanistic study shows that glycine signals via GLRA1 and calmodulin to stabilize ER Ca2+ in β-cells, thereby supporting insulin biosynthesis and cell survival. Dietary glycine deficiency impaired insulin secretion and reduced islet mass, linking amino acid availability to β-cell calcium homeostasis.
Impact: Identifies a previously unappreciated receptor-mediated pathway coupling amino acid signaling to ER calcium and insulin biosynthesis, opening avenues for metabolic and pharmacologic modulation.
Clinical Implications: Suggests that targeting GLRA1–calmodulin signaling or restoring glycine availability could preserve β-cell function; motivates translational studies of dietary supplementation or receptor modulators.
Key Findings
- Glycine activates a GLRA1–calmodulin axis that maintains ER Ca2+ homeostasis in β-cells.
- Dietary glycine deficiency reduces islet mass, impairs insulin secretion, and worsens glucose intolerance.
- Stabilization of ER Ca2+ links amino acid signaling to insulin biosynthesis and β-cell survival.
Methodological Strengths
- Integrated in vivo dietary manipulation with cellular mechanistic assays
- Direct interrogation of ER calcium homeostasis in β-cells
Limitations
- Preclinical models limit direct generalizability to humans
- Incomplete mechanistic details in abstract regarding upstream/downstream effectors
Future Directions: Test whether glycine supplementation or GLRA1 modulators preserve β-cell function in diabetic models and early-phase human studies; map downstream signaling and safety.
Glycine, a non-essential amino acid, has been linked to improved metabolic health and enhanced insulin secretion, yet its mechanistic role in β-cell function remains poorly defined. Here, we identify a glycine-GLRA1-calmodulin signaling axis that regulates endoplasmic reticulum (ER) calcium homeostasis to support insulin biosynthesis and β-cell survival. Dietary glycine deficiency impairs insulin secretion, reduces islet mass, and worsens glucose intolerance, while overexpression of serine hydroxymethyltransferase 2 (
3. Artificial Intelligence-Enabled Analysis of Radiology Reports: Epidemiology and Outcomes of Incidental Thyroid Findings.
Using a transformer-based NLP pipeline across 115,683 patients without prior thyroid disease, incidental thyroid findings were identified in 7.8% and strongly associated with downstream ultrasound, biopsy, thyroidectomy, and thyroid cancer diagnoses, mostly papillary and often small. Documentation of nodule features was poor, underscoring the need for standardized reporting and selective follow-up.
Impact: Quantifies the magnitude and downstream consequences of incidental thyroid findings using validated AI at scale, directly informing de-implementation and reporting standards to reduce overdiagnosis.
Clinical Implications: Adopt standardized, TIRADS-aligned reporting with mandatory size and key features; implement selective follow-up pathways to avoid unnecessary biopsies and surgeries for low-risk incidental nodules.
Key Findings
- Incidental thyroid findings occurred in 7.8% of 115,683 adults; 92.9% were nodular.
- ITFs markedly increased downstream ultrasound, biopsy, thyroidectomy, and cancer diagnoses (e.g., OR for cancer 61.7).
- Nodule features were poorly documented (size in 44%; other features <15%), highlighting reporting gaps.
Methodological Strengths
- Transformer-based NLP validated and deployed across multi-modality, multi-site reports
- Large cohort with clear downstream outcome ascertainment and multivariable modeling
Limitations
- Retrospective design subject to documentation bias and residual confounding
- Imaging feature extraction limited by inconsistent report detail
Future Directions: Prospectively evaluate AI-augmented reporting templates and selective follow-up protocols on procedure rates, cancer yield, and patient outcomes.
CONTEXT: Incidental thyroid findings (ITFs) are increasingly detected on imaging performed for non-thyroid indications. Their prevalence, features, and consequences remain undefined. OBJECTIVE: To develop, validate, and deploy a natural language processing (NLP) pipeline to identify ITFs in radiology reports and assess their prevalence, features, and clinical outcomes. DESIGN: Retrospective cohort study. SETTING: Mayo Clinic sites (Rochester, Arizona, Florida, Mayo Clinic Health System). PARTICIPANTS: Adults without prior thyroid disease undergoing thyroid-capturing imaging from July 1, 2017, to September 30, 2023. A transformer-based NLP pipeline identified ITFs and extracted nodule characteristics from image reports from multiple modalities and body regions. OUTCOMES: ITF prevalence, downstream thyroid ultrasound, biopsy, thyroidectomy, and cancer diagnosis. Logistic regression identified demographic and imaging-related factors. RESULTS: Among 115,683 patients (mean age, 56.8 [SD 17.2]; 52.9% women), 9,077 (7.8%) had an ITF (92.9% nodular). ITFs were more likely in women, older adults, higher BMI, and in imaging ordered by specialties different from Emergency Medicine. Compared with chest CT, ITFs were more likely via neck CT, PET, and nuclear medicine scans. Nodule characteristics were poorly documented, with size reported in 44% and other features in fewer than 15%. Compared with patients without ITFs, those with ITFs had higher odds of thyroid nodule diagnosis (OR 45, 95%CI 41.1-49.3) biopsy (OR 46.8, 95%CI 39.0-56.2) thyroidectomy (OR 55.8, 95%CI 31.3-99.3) and thyroid cancer diagnosis (OR 61.7, 95%CI 38.6-98.5). Most cancers were papillary (88.5%), and larger when detected after ITFs (2 cm-SD 1.4) vs no ITF (1.3 cm-SD 0.8). CONCLUSIONS: ITFs were common and strongly associated with cascades leading to detection of small, low-risk cancers, highlighting their role in overdiagnosis and the need for standardized reporting and more selective follow-up.